SCHEMBL3674461

SCHEMBL3674461

Cc1ccc(C(=O)N2CCN(c3ccc(C(=O)NCCCOC(C)C)cn3)CC2)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
SCD O00767 2/20 0.53
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
EGLN1 Q9GZT9 2/20 0.45
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 1/20 0.44
NAMPT P43490 1/20 0.43
FOLH1 Q04609 1/20 0.43
ALDH1A1 P00352 2/20 0.43
GSK3B P49841 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3671418 0.92 KDM4E (0.57) LMNAKDM4EHTTSMN1; SMN2SCD
SCHEMBL3674361 0.90 SMN1; SMN2 (0.55) LMNAKDM4EHTTSMN1; SMN2SCD
SCHEMBL3672273 0.89 LMNA (0.54) LMNAKDM4EHTTSMN1; SMN2SCD
SCHEMBL3673516 0.88 LMNA (0.59) LMNAKDM4EHTTSMN1; SMN2SCD
SCHEMBL3670642 0.87 LMNA (0.58) LMNAKDM4EHTTSMN1; SMN2SCD
SCHEMBL3676764 0.86 LMNA (0.57) LMNAKDM4EHTTSMN1; SMN2SCD
SCHEMBL3679020 0.86 SCD (0.51) SCDKMT2AMEN1EGLN1TSHR
SCHEMBL3675294 0.86 SMN1; SMN2 (0.56) LMNAKDM4EHTTSMN1; SMN2SCD
SCHEMBL3675229 0.84 SCD (0.53) LMNASMN1; SMN2SCDEGLN1TSHR
SCHEMBL3666675 0.84 SCD (0.51) LMNAKDM4ESCDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT LMNA 175/4885KDM4E 3385/4885HTT 1288/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 LMNA 369/4885KDM4E 4395/4885HTT 8/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT LMNA 175/4885KDM4E 3385/4885HTT 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.